Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors

Yun Jung Choi(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jae Cheol Lee(Ulsan College)
PLoS ONE
December 5, 2013
10.1371/journal.pone.0081393
Cited by 11

Related Papers

Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer
|Oncotarget|2016|70
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer
|Nature Cancer|2023|46
Autophagosome-Mediated EGFR Down-Regulation Induced by the CK2 Inhibitor Enhances the Efficacy of EGFR-TKI on EGFR-Mutant Lung Cancer Cells with Resistance by T790M
|PLoS ONE|2014|28
AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells
|PLoS ONE|2015|25
The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02–011 Overcomes C797S-Mediated Resistance in Lung Cancer
|Cancer Research|2022|5